Medtronic PLC Earnings - Q1 2026 Analysis & Highlights
Medtronic delivered its strongest top-line performance in 10 years during fiscal 2026, driven by exceptional growth in Cardiac Ablation Solutions and continued momentum across its portfolio, while guiding for mid-single-digit organic growth in 2027 despite headwinds from tariffs and the planned MiniMed separation.
Key Financial Results
Q4 2026 revenue reached $9.8 billion, up 9.9% on a reported basis and 6.6% organically, representing a 60 basis point acceleration from the prior quarter.
Full-year fiscal 2026 revenue totaled $36.4 billion, up 8.4% reported and 5.8% organically, marking the strongest top-line performance in 10 years.
Q4 adjusted EPS was $1.55 and full-year adjusted EPS was $5.53, both ahead of expectations.
Adjusted gross margin was 65.4% in Q4, up 30 basis points year-over-year and up 50 basis points sequentially.
Adjusted operating margin was 25.5% in Q4, which included 160 basis points of impact from the MiniMed Blackstone payment and 80 basis points from tariffs.
Free cash flow was $5.4 billion in fiscal 2026, the strongest since 2022 and ahead of expectations.
Cash and investments ended the year at $9.2 billion, positioning the company favorably to execute on M&A opportunities.
Business Segment Results
Cardiovascular delivered 10% revenue growth in Q4, led by 14% in the US and 7% in international markets.
Cardiac Ablation Solutions (CAS) delivered 78% worldwide growth and gained an additional 8 points of US market share, with the business now annualizing over $2 billion in revenue.
Pulmonary Field Ablation (PFA) saw exceptional global growth of 145%, with Sphere-9 continuing to demonstrate broad versatility.
Cardiac Rhythm Management delivered 5% growth in both US and international markets, with defibrillation delivering mid-single digit growth including high-teens in ICD and mid-60s in EV-ICD.
Cardiac Pacing Therapies delivered mid-single digit growth, driven by mid-teens in Micra and high-teens in the SelectSecure 3830 lead.
Structural Heart performance was flat in the quarter, with strong international performance offset by softer US performance related to low-risk data, though weekly US procedure volumes have stabilized over the last eight weeks.
Renal Denervation (Symplicity) is now annualizing at $100 million, with doubled average weekly procedure volumes since the National Coverage Determination and significant uptick in prior authorization approvals.
Neuroscience delivered 3% revenue growth globally, driven by 6% in international markets.
Cranial & Spinal Technologies (CST) was up 3% in both US and international markets, with Core Spine gaining share growing 6% on continued ModuleX expansion.
Stealth AXiS navigation platform achieved FDA clearance across Spine, Cranial, and ENT indications, with CE Mark for Spine and Cranial, and early commercial launch progressing well with strong physician feedback and sales off to a strong start.
Specialty Therapies delivered 3% growth, with Neurovascular up 6% driven by 11% growth in Hemorrhagic including healthy adoption of Neuroguard and Artisse.
Medical Surgical delivered 5% growth globally, including 8% in the US.
Surgical revenue increased 3% globally, split evenly between US and international markets, driven by high-single digit growth in Advanced Energy and Wound Management plus increased contribution from Hugo.
Endoscopy delivered high-single digit growth, driven by strong adoption of Endoflip in the US and Western Europe and market share gain in Nexpowder in the US.
Acute Care and Monitoring was up 11%, including high-teens growth in the US, driven by mid-teens growth in Nellcor pulse oximetry, high-single digit growth in respiratory and airways, and mid-single digit in perioperative.
Diabetes business delivered 15% reported growth or 8.1% organic, driven by strong international execution and continued momentum in US CGM and new patient starts.
Capital Allocation
Medtronic closed or announced nearly $2 billion of additional investments in M&A and venture capital strategy during Q4.
Recent M&A is expected to contribute approximately $150 million to inorganic revenue growth in fiscal 2027 and be a healthy contributor to the organic base in out-years.
The company made 16 venture investments in fiscal 2026 totaling approximately $250 million, each in growth-accretive adjacencies.
Key M&A transactions announced include the CathWorks transaction in Coronary, planned acquisitions of Scientia and SPR Therapeutics, and investments in Beluga Medical and CardioACC for ICE catheter technology.
MiniMed IPO was completed in early March, establishing it as a standalone publicly traded company.
Capital expenditures grew at a significantly lower rate than revenue, with CapEx spend up roughly $50 million.
Industry Trends and Dynamics
The Cardiac Ablation Solutions market grew approximately 20% in Q4, with Medtronic expected to grow north of two times the market rate in fiscal 2027 with mid- to high-teens market growth anticipated.
Hypertension represents a massive unmet need, with roughly 18 million people still living with uncontrolled hypertension in the US alone despite the use of multiple medications.
A 10-point reduction in blood pressure is proven to show greater than 20% reduction in major cardiovascular events like heart attack, stroke, and heart failure.
The FFRangio System addresses a $1 billion segment growing in the low-double digits, representing a non-invasive technology poised to disrupt the gold standard traditional wire-based FFR.
Neuromodulation is an attractive space growing over 20% annually, as demonstrated by Medtronic's expansion in BVNA and planned acquisition of SPR Therapeutics.
Robotics penetration in spine surgery remains in the high-single digits, indicating significant runway ahead for adoption.
China remains a growth market for Medtronic, with the team navigating Value-Based Procurement (VBP) dynamics well, increasing procedures and lowering costs while maintaining growth at the corporate average.
Competitive Landscape
Medtronic is the number one player and category leader across each segment in Neuroscience with the most comprehensive portfolio.
In Cardiac Ablation Solutions, Medtronic is marching towards market leadership with approximately 15% share and gaining additional share points.
Medtronic stands apart as the proven platform in the renal denervation category with enormous unmet need, with robust and growing clinical evidence, a broad label, expanding reimbursement, and growing demand from both physicians and patients.
In Cardiac Rhythm Management, the company is innovating and growing the market where other companies see a mature market, with strong momentum from recently launched products like OmniaSecure Defibrillation lead.
Medtronic has a strong commercial footprint in Peripheral Vascular that supports the launch of new products like Liberant mechanical thrombectomy device.
Macroeconomic Environment
Tariffs impacted the business by $74 million or 80 basis points in Q4, in line with expectations.
Foreign exchange provided an approximate 80 basis points tailwind to gross margin in Q4.
The macro backdrop has been challenging and dynamic, but MedTech is structurally resilient because the fundamentals are durable.
Medtronic has embedded a roughly 1 point headwind from increased fuel and transportation costs due to the conflict in the Middle East.
Medtronic colleagues in the Middle East and impacted countries have remained focused on serving customers and patients despite the ongoing conflict.
Growth Opportunities and Strategies
Cardiac Ablation Solutions ecosystem expansion includes launching Sphere-9 in Japan, securing FDA approval for US VT pivotal trial to begin enrolling in H1 FY 2027, launching Sphere-360 catheter in Europe, and making two targeted investments in ICE catheter technology.
Symplicity Spyral represents a novel, one-time, minimally-invasive approach to treat hypertension with a physician finder spanning 200 doctors across more than 300 accounts.
Hugo surgical robotic system is showing meaningful impact with worldwide procedure volume growth 2x to 3x the market and utilization increasing, with urology launch in the US and submissions for FDA 510(k) clearance for general surgery and gynecologic indications.
Touch Surgery digital ecosystem continues to represent a clear advantage with over 1,400 installations, up 30% plus sequentially.
Altaviva for urge urinary incontinence is building momentum with nearly 1,000 physicians trained since launch, active implanters up three times sequentially, and patients treated up two and a half times.
Medtronic is expanding its entire EP ecosystem by expanding geographically into new indications and with an exciting cadence of new innovation.
Stealth AXiS is a force multiplier driving pull-through across planning, robotics, and the broader AiBLE ecosystem while promoting adoption of robotics in spine surgery.
Scientia acquisition will meaningfully expand the neurovascular platform with differentiated guidewire technologies for stroke, enabling every neurovascular procedure to start with Medtronic.
SPR Therapeutics acquisition will build out the portfolio of chronic pain management therapies for peripheral nerve stimulation.
Pulnovo investment addresses pulmonary artery denervation as a first-of-its-kind minimally invasive system.
ViaVerte distribution agreement brings an FDA-cleared solution for chronic vertebrogenic back pain.
Medtronic is deliberately building its robotics program by driving utilization and procedure growth globally, making steady progress in the United States and investing to strengthen the broader surgical franchise.
Financial Guidance and Outlook
Fiscal 2027 organic revenue growth guidance is 6.75% to 7.25%, including approximately 11.5% to 12% organic growth in the first quarter.
Guidance includes a roughly 25 basis points tailwind from the Diabetes business and incorporates the benefit from the additional selling week, which is expected to contribute approximately 125 basis points to full-year growth and 500 to 600 basis points in the first quarter.
Foreign exchange is expected to be neutral to roughly $100 million headwind for the full year, with an approximate neutral to $50 million tailwind to the first quarter.
Fiscal 2027 margin is expected to be roughly in line with the previous year, excluding tariffs, with pricing and COGS efficiency programs expected to offset the impact of business mix.
Tariff impact to COGS is anticipated at approximately $250 million in total, including $75 million in the first quarter, an increase of $65 million versus prior year.
Fiscal 2027 gross margin is expected to decrease by roughly 20 basis points including tariffs.
Fiscal 2027 operating margin is expected to be up 60 basis points, driven by the absence of Blackstone milestone payments and operating leverage.
A 200 basis points headwind is expected below the operating profit line, driven by an increase in net interest expense and a slightly higher tax rate.
Fiscal 2027 EPS guidance is $5.90 to $6.00.
First quarter 2027 EPS is expected in the range of $1.38 to $1.40, including 600 to 700 basis points benefit from the extra selling week and roughly neutral impact from foreign exchange.
The company is factoring 2% dilution from M&A, roughly 1 point higher than shared last quarter due to earlier-than-anticipated timing of several deals.
Medtronic is taking a conservative approach on MiniMed separation, including the full year of the Diabetes business in estimates and assuming no separation share count benefit in fiscal 2027, with potential upside if separation occurs prior to year-end.
Cardiovascular business is expected to have performance in line with 2026 with strong momentum continuing, particularly in CAS with continued early innings development and significant headroom for catheter sales growth.
Cardiac Rhythm Management is expected to continue strong mid-single digit growth driven by innovation from Micra, Omnia, and EV-ICD.
Ardian is expected to continue growing significantly into 2027 and beyond, currently annualizing about $100 million in revenue.
Structural Heart guidance is prudent based on business stabilization over recent weeks.
Neuroscience portfolio is expected to accelerate, with every single franchise expected to accelerate going forward including CST with Stealth AXiS, Neurovascular with innovation, and Pelvic Health with Altaviva.
Medical Surgical growth is expected to normalize from Q4 levels, with the company not reflecting the full Q4 run rate in 2027 guidance.
MiniMed is expected to bring about 20 to 25 basis points of growth contribution in 2027.
Leadership Transition
Brett Wall is leaving Medtronic after a 25-year career, having played a defining role in shaping the Neuroscience portfolio including establishing interventional stroke as a global standard of care.
Dr. Kweli Thompson will step into the role of Executive Vice President and President of the Neuroscience portfolio, bringing a proven track record of execution and deep clinical and operational experience from leading the CRM business.
